With its 2009 year-end results (and 2010 guidance) due out on Thursday (pre-market) morning, Vertex was just upgraded to "outperform" by Oppenheimer -- per Business Week's online edition:
. . . .An Oppenheimer analyst upgraded the stock of Vertex Pharmaceuticals on the potential of its hepatitis C treatment.
Analyst Dr. Brian Abrahams said Monday that he believes it will be a significant year for the Cambridge, Mass., company, with the experimental drug telaprevir driving its stock.
He upgraded company shares to "outperform" from "perform". . . .
Of course, telaprevir is well-ahead of legacy-Schering-Plough's boceprevir -- in the race for a next-gen Hep C treatment regimen -- on both the timeline-to-approval, and previous Hep C non-responder efficacy measures.
4 comments:
http://www.dilbert.com/strips/comic/2010-02-02/
Great one -- with corporate choppers, yet again!
But isn't the currently PC/polite term (in the last line) "little people"? Thanks!
Namaste
Since when has the CEO ever cared about the 'little people's' feelings?
Indeed. Well put. [I think a rim-shot ought to follow yours.]
Namaste
Post a Comment